Nicardipine: Comprehensive Drug Monograph

Pharmacokinetic Profile

Half-Life

Oral terminal ~8.6 h; IV declines tri-exponentially (α 2.7 min · β 44.8 min · γ 14.4 h)

Metabolism

Hepatic CYP2C8, CYP2D6, and CYP3A4 (extensive first-pass)

Protein Binding

>95% (mainly albumin and α₁-acid glycoprotein)

Bioavailability

~35% oral at steady state (saturable first-pass; non-linear PK)

Volume of Distribution

~8.3 L/kg (non-compartmental, IV)

Clinical Information

Drug Class

Dihydropyridine CCB

Available Strengths

PO IR: 20, 30 mg capsules · SR: 30, 45, 60 mg capsules · IV ampule 25 mg/10 mL · IV premixed 20 mg/200 mL or 40 mg/200 mL

Route

Oral (IR, SR), continuous IV infusion

Renal Adjustment

Yes — titrate gradually; higher AUC observed

Hepatic Adjustment

Yes — start lower; t½ prolonged to ~19 h in cirrhosis

Pregnancy

Use only if benefit outweighs risk; IV often selected for severe HTN/preeclampsia

Lactation

Minimal milk transfer reported; FDA labeling advises against breastfeeding while on therapy — local guidelines vary

Schedule / Legal

Rx only (non-controlled)

Generic Available

Yes (oral and IV)

Indications

Indication	Approved Population	Therapy Type	Status
Essential hypertension — oral immediate-release	Adults	Monotherapy or combination	FDA Approved
Essential hypertension — oral sustained-release	Adults	Monotherapy or combination	FDA Approved
Chronic stable (effort-associated) angina	Adults — oral IR only	Monotherapy or combination with beta-blockers	FDA Approved
Short-term treatment of hypertension when oral therapy is not feasible or not desirable	Adults — IV infusion	Monotherapy	FDA Approved

Nicardipine occupies a useful niche among the dihydropyridine calcium channel blockers because it is one of the few agents available in both oral and intravenous formulations. The IV preparation has become a workhorse in critical care and perioperative settings for blood-pressure control, owing to its rapid onset, predictable titration, and largely vascular (rather than cardiac) activity.

For chronic hypertension, oral nicardipine is rarely a first-line choice — long-acting agents such as amlodipine or felodipine are typically preferred for adherence reasons. Oral immediate-release nicardipine retains a role mainly for chronic angina, while sustained-release formulations can be used for stable hypertension in selected patients.

Off-Label Uses

Hypertensive emergency / urgency — IV titration to a target MAP reduction in critical care. (Evidence: high — multiple RCTs; supported by ACC/AHA guidance)

Severe hypertension in pregnancy / preeclampsia — IV alternative when labetalol is contraindicated or ineffective. (Evidence: high — RCTs vs labetalol show comparable efficacy)

Acute ischemic and hemorrhagic stroke BP control — preferred IV agent in many neurocritical care protocols for its predictable titration. (Evidence: moderate — observational and protocol-based)

Cerebral vasospasm after aneurysmal subarachnoid hemorrhage — intra-arterial or IV for delayed cerebral ischemia. (Evidence: moderate — observational; intra-arterial is the more common route)

Perioperative and post-cardiac-surgery hypertension — IV titration. (Evidence: high — established in cardiac surgery protocols)

Aortic dissection BP control — IV adjunct after a beta-blocker has reduced shear stress. (Evidence: moderate — guideline-supported)

Dose

Dosing

Doses below are organised by clinical scenario rather than by formulation strength. Many clinicians underdose IV nicardipine on initiation because the early infusion rate appears modest; a structured titration plan (5 → 7.5 → 10 → 12.5 → 15 mg/h) at 5–15-minute intervals is essential to reach goal blood pressure.

Clinical Scenario	Starting Dose	Maintenance Dose	Maximum Dose	Notes
Hypertension — oral immediate-release, treatment-naïve adult	20 mg PO TID	20–40 mg PO TID	120 mg/day	Allow at least 3 days between dose adjustments to reach steady state IR is the only oral form approved for chronic angina
Hypertension — oral sustained-release, treatment-naïve adult	30 mg PO BID	30–60 mg PO BID	120 mg/day	Capsules must be swallowed whole — do not crush, chew, or split. When converting from IR to SR, start with the patient’s existing total daily IR dose split BID and re-titrate SR has not been studied in severe hepatic impairment
Chronic stable angina — oral IR	20 mg PO TID	20–40 mg PO TID	120 mg/day	Avoid abrupt discontinuation; can be combined with beta-blockers or long-acting nitrates with caution
Acute hypertension — IV, BP-naïve adult	5 mg/h IV continuous infusion	Typical effective range 3–10 mg/h	15 mg/h	Increase by 2.5 mg/h every 5 min (rapid titration) or every 15 min (gradual titration); after the BP goal is reached using rapid titration, decrease infusion to 3 mg/h to maintain BP falls within minutes; ~50% of ultimate effect by ~45 min; 50% offset after stopping is ~30 min
Acute hypertension — IV, transitioning from oral nicardipine	20 mg PO q8h ≈ 0.5 mg/h IV 30 mg PO q8h ≈ 1.2 mg/h IV 40 mg PO q8h ≈ 2.2 mg/h IV	Adjust to BP response	15 mg/h	Per FDA label, these IV rates approximate average plasma concentration equivalence to the oral regimen at steady state Always re-titrate to BP rather than relying on the conversion
Hypertensive emergency (off-label) — IV	5 mg/h IV	Titrate by 2.5 mg/h every 5 min to target MAP	15 mg/h	Aim for ≤25% reduction in MAP within the first hour, then a further reduction over the next 2–6 h; match end-organ goals (stroke, dissection, pulmonary edema)
Severe preeclampsia / hypertensive crisis in pregnancy (off-label) — IV	2.5–5 mg/h IV	3–7.5 mg/h IV	15 mg/h	Useful when labetalol is contraindicated (e.g., asthma, severe bradycardia); coordinate carefully with magnesium sulfate (additive hypotension)
Cerebral vasospasm post-SAH (off-label) — intra-arterial / IV	IA: institutional protocol (typically a few mg per vessel territory)	Adjusted by the interventionalist	Local protocols apply	Specialist (neurointerventional) administration only Sustained IV infusion has been used in some centres for prophylaxis
Renal impairment	PO IR 20 mg BID initially (per FDA label for oral)	Titrate slowly; usual maintenance often achievable	120 mg/day (oral); 15 mg/h (IV)	IV nicardipine in moderate renal impairment shows lower clearance and higher AUC — start at the lower end of the IV range and titrate gradually
Hepatic impairment	PO IR 20 mg BID	Titrate cautiously; longer interval to steady state	Use lowest effective dose	SR has not been studied in severe liver disease; in cirrhosis, AUC is approximately 4-fold higher and t½ prolonged to ~19 h Avoid IV in severe hepatic dysfunction unless no alternative
Older adults (≥ 65 y)	Same starting dose as adults (PO 20 mg TID; IV 5 mg/h)	Titrate cautiously — orthostatic risk	As above	Slower titration; volume depletion increases hypotension risk
Pediatric (off-label; not FDA-approved)	IV: ~0.5–1 mcg/kg/min	~1–4 mcg/kg/min (mean effective ~1.8 mcg/kg/min in published series)	Local protocols (commonly up to ~4–5 mcg/kg/min)	Used in pediatric ICU for hypertensive crises Safety and effectiveness in patients < 18 years have not been established by FDA

Clinical Pearl — Infusion Site and Concentration

IV nicardipine is associated with peripheral venous irritation and phlebitis. Per the FDA label, the ampule must be diluted to 0.1 mg/mL before use, infusion through a large peripheral vein or central vein is preferred, and the peripheral site should be changed every 12 hours to reduce local reactions. For prolonged infusions, central access is favoured whenever practical.

Switching from IV to Oral

If switching to oral nicardipine, the FDA label instructs giving the first oral dose 1 hour before stopping the IV infusion. If switching to a different oral antihypertensive, that agent should be initiated at the time of IV discontinuation. Re-check BP within 30–60 minutes of the changeover.

Pharmacology

Mechanism of Action

Nicardipine is a second-generation dihydropyridine that selectively inhibits the slow inward (L-type) calcium current in vascular smooth muscle and, to a much lesser degree, cardiac myocytes. Blocking calcium entry through these channels reduces intracellular calcium and the calcium–calmodulin–myosin-light-chain-kinase signal that produces vascular tone, leading to arterial smooth-muscle relaxation and a fall in systemic vascular resistance.

Compared with verapamil and diltiazem, nicardipine has minimal direct effect on sinoatrial or atrioventricular conduction at therapeutic doses, so it does not slow the heart rate; instead, baroreflex activation may produce a modest reflex tachycardia, particularly with rapid IV titration. Its preferential coronary and cerebral vasodilatory action also explains its use for both anginal symptoms and for cerebral perfusion management in subarachnoid hemorrhage.

ADME Profile

Parameter	Value	Clinical Implication
Absorption	Completely absorbed orally; absolute bioavailability ~35% at steady state due to saturable first-pass; oral plasma levels detectable from ~20 min, broad Tmax of 1–4 h with SR; high-fat meal lowers Cmax/AUC by 20–30% with SR	Onset within 20 minutes orally; oral PK is non-linear because doubling the dose can produce a 4–5-fold rise in Cmax — titration must be cautious at higher doses
Distribution	Vd ~8.3 L/kg (non-compartment, IV); protein binding >95% across a wide range; small amounts cross placenta and into breast milk	Widely tissue-distributed including coronary and cerebral vasculature; high protein binding limits free fraction shifts in most clinical situations
Metabolism	Extensive hepatic biotransformation by CYP2C8, CYP2D6, and CYP3A4; nicardipine itself inhibits CYP3A4, CYP2D6, CYP2C8, and CYP2C19 (it does not induce its own metabolism)	Strong CYP3A4 modulators alter exposure; nicardipine itself raises levels of CYP3A4 substrates such as cyclosporine and tacrolimus; severe hepatic dysfunction prolongs t½ to ~19 h and increases AUC ~4-fold
Elimination	After an oral radioactive dose: ~60% excreted in urine, ~35% in faeces; <1% as unchanged drug in urine; oral terminal t½ ~8.6 h. IV plasma decline is tri-exponential (α 2.7 min, β 44.8 min, γ 14.4 h); IV PK is linear over 0.5–40 mg/h	No specific dose adjustment for renal failure based on metabolite handling, but clinical sensitivity is increased — titrate slowly. After stopping IV, ~50% offset of effect occurs in about 30 minutes

Side Effects

The adverse-effect profile of nicardipine is dominated by predictable consequences of arterial vasodilation: headache, flushing, edema, and reflex tachycardia. Frequencies below are taken directly from the FDA prescribing information adverse-reaction tables and should be referenced against the appropriate formulation: rates differ substantially between IV use, oral immediate-release (IR), and oral sustained-release (SR). Clinicians should note that the SR adverse-event table in the current FDA label reports rates of “probably drug-related” events versus placebo, and several events occurred at rates similar to or below placebo.

≥10% Very Common (IV formulation)

Adverse Effect	Incidence (placebo)	Clinical Note
Headache (IV)	15% (2% placebo)	From two pooled placebo-controlled IV trials (n=144 vs n=100); responsive to acetaminophen and usually attenuates as the infusion rate is reduced

No oral formulation event reaches the ≥10% threshold in the current FDA placebo-controlled tables. Older comparative oral data (e.g., Sorkin and Clissold, Drugs 1987) report higher rates for headache (up to ~19%) and pedal edema (up to ~12%) with oral IR therapy in some cohorts.

1–10% Common

Adverse Effect	Incidence (placebo)	Clinical Note
Hypotension (IV)	6% (1% placebo)	Usually resolves on dose reduction; permanent discontinuation rarely needed
Nausea / vomiting (IV)	5% (1% placebo)	Generally mild and self-limiting
Tachycardia (IV)	4% (0% placebo)	Mean HR rise of 7–8 bpm in placebo-controlled IV trials; reflex sympathetic response, more pronounced with rapid up-titration
Pedal edema (oral IR — hypertension)	7–8%	Per FDA label, dose-related; not a sign of fluid overload — does not respond well to diuretics; consider switching to a non-DHP CCB if disabling
Pedal edema (oral SR — hypertension)	5.9% (1.4% placebo)	The only event reported as dose-related in the SR placebo-controlled trials
Vasodilatation / flushing (oral SR)	4.7% (1.4% placebo)	Tends to settle with continued therapy
Headache (oral SR)	6.2% (7.1% placebo)	Reported at a similar rate to placebo in SR trials, so causal attribution is uncertain; nonetheless headache remains the most frequent reason for discontinuation in clinical practice
Palpitation (oral SR)	2.8% (1.4% placebo)	Perceived reflex tachycardia; consider longer-acting CCB if persistent
Nausea (oral SR)	1.9% (0.7% placebo)	Usually mild; food may help
Dizziness (oral SR)	1.6% (0.7% placebo)	Most likely with first dose, dose increases, or volume depletion
Postural hypotension (oral SR)	0.9% (0% placebo)	Counsel patients to rise slowly; review concurrent diuretics
Increased angina on initiation (oral IR)	~7% (4% placebo)	Per FDA label warning; class effect of short-acting DHPs; reassess for ischemia and consider an alternative agent
Phlebitis / IV-site irritation	~5–10% (IV)	Reported in postmarketing surveillance; lower with dilute solution and central administration; rotate peripheral sites every 12 h
Vasodilatation / pedal edema / asthenia / dizziness (oral SR — chronic angina population, n=91 open-label)	5.5% / 4.4% / 4.4% / 3.3%	From the SR open-label angina cohort; small sample size limits inference

Serious Serious Adverse Effects (regardless of frequency)

Adverse Effect	Estimated Frequency	Typical Onset	Required Action
Symptomatic hypotension	~6% (IV) / Rare (oral)	Minutes after IV titration; first dose oral	Reduce or stop infusion; positioning; IV fluids; IV calcium gluconate may help reverse calcium channel blockade in overdose
New or worsening angina / acute MI	~7% on initiation of oral IR (vs 4% placebo)	First days of therapy	Stop drug; ECG and troponin; switch to longer-acting CCB or alternative class
Heart-failure exacerbation / negative inotropy	Rare	Days to weeks	Discontinue in significant LV dysfunction; reassess regimen; titrate slowly when combined with a beta-blocker
Profound bradyarrhythmia / heart block	Very rare	During infusion or overdose	Stop drug; assess for concurrent AV-nodal blocking agents (beta-blocker, digoxin)
Hepatic enzyme abnormalities	Rare (postmarketing)	Weeks	Discontinue if ALT/AST rise with symptoms; usually reversible
Hypersensitivity / allergic reaction	Rare (postmarketing)	Any time	Emergency management; permanent discontinuation
Severe phlebitis / venous thrombosis (peripheral IV)	Uncommon	After ~12+ hours of peripheral infusion	Switch to central access; rotate site; supportive measures
Worsening renal function in pre-existing renal disease	Rare	Weeks	Recheck creatinine within 1–2 weeks of titration; reduce dose or switch agent if rising
Pulmonary edema (especially when IV nicardipine combined with IV magnesium in obstetrics)	Uncommon	Hours	Stop infusion(s); diuresis if appropriate; restrict fluids per obstetric protocol

Discontinuation Treatment Discontinuation Rates (FDA Label Data)

Adults — Oral SR (Hypertension)

~9% withdrew prematurely

Top reasons (events ≥1%): headache 2.5%, palpitation 2.2%, dizziness 1.9%, asthenia 1.9%, pedal edema 1.2%, nausea 1.2%

Adults — IV (Acute HTN)

~12% discontinued

Top reasons: hypotension, headache, tachycardia (per pooled placebo-controlled IV trials, n=144)

Reason for Discontinuation (Oral SR vs Placebo)	SR Incidence	Placebo
Headache	2.5%	1.4%
Palpitation	2.2%	0.7%
Dizziness	1.9%	0.7%
Asthenia	1.9%	0%
Pedal edema	1.2%	0%
Nausea	1.2%	0%
Rash	0.9%	0.7%
Tachycardia	0.9%	0%

Management Pearl — Pedal Edema vs Volume Overload

Calcium-channel-blocker edema is a precapillary vasodilatory phenomenon, not a salt-and-water retention problem. Loop diuretics are largely ineffective and may worsen orthostasis. Practical options include reducing the dose, switching to a non-dihydropyridine CCB, or co-prescribing a renin–angiotensin system inhibitor, which can reduce edema by post-capillary venodilation.

Int

Drug Interactions

Most clinically meaningful interactions arise through cytochrome P450 enzymes — nicardipine is a substrate of CYP2C8, CYP2D6, and CYP3A4 and a known inhibitor of CYP3A4, CYP2D6, CYP2C8, and CYP2C19. The drug also reduces clearance of several narrow-therapeutic-index agents (cyclosporine, tacrolimus), and additive hypotensive interactions are common when nicardipine is combined with other vasodilators or magnesium sulfate in the obstetric setting.

Major Strong CYP3A4 inhibitors (clarithromycin, ketoconazole, itraconazole, ritonavir)

MechanismInhibition of nicardipine biotransformation

EffectElevated plasma concentrations and BP-lowering effect

ManagementAvoid combination if possible; if required, use a lower starting dose and monitor BP closely

FDA PI / Lexicomp

Major Cyclosporine

MechanismNicardipine inhibits hepatic microsomal enzymes including CYP3A4

EffectElevated cyclosporine plasma levels with risk of nephrotoxicity

ManagementClosely monitor cyclosporine concentrations and reduce its dose accordingly when nicardipine is added or removed (per FDA label)

FDA PI

Major Tacrolimus

MechanismCYP3A4 inhibition by nicardipine

EffectElevated tacrolimus exposure with risk of nephrotoxicity

ManagementClosely monitor tacrolimus trough concentrations and adjust dose accordingly (per FDA label)

FDA PI

Major IV magnesium sulfate (preeclampsia)

MechanismAdditive vasodilation and possibly enhanced neuromuscular blockade

EffectReports of severe hypotension and pulmonary edema; rare neuromuscular weakness

ManagementCombination is acceptable in obstetric care, but BP must be checked frequently during titration; have IV calcium gluconate available; restrict fluids per obstetric protocol

Case reports / obstetric protocols

Major Fentanyl anesthesia (with concurrent beta-blocker)

MechanismAdditive vasodilation and sympathetic blockade under anaesthesia (per FDA label)

EffectSevere hypotension reported during induction or maintenance

ManagementUse lower nicardipine infusion rates intraoperatively and ensure adequate volume — increased fluid volume may be required if hypotension occurs

FDA PI

Moderate CYP3A4 inducers (rifampin, phenytoin, carbamazepine, St John’s wort)

MechanismInduction of nicardipine metabolism

EffectReduced exposure and possible loss of antihypertensive efficacy

ManagementMonitor BP; titrate dose upward as needed or select an alternative agent

Lexicomp

Moderate Beta-blockers

MechanismAdditive antihypertensive effect; partial offset of reflex tachycardia

EffectPer FDA label, the combination is generally well tolerated; rare additive negative inotropy in compromised LV function

ManagementCombination usually safe; titrate slowly when combined with a beta-blocker in heart failure or significant LV dysfunction

FDA PI

Moderate Digoxin

MechanismPossible reduction in digoxin clearance

EffectPer FDA label, nicardipine usually does not alter digoxin levels — but other CCBs can, so monitoring is prudent

ManagementCheck digoxin level after concomitant therapy is initiated

FDA PI

Moderate Cimetidine

MechanismCimetidine inhibits hepatic CYP3A4

EffectPer FDA label, cimetidine increases nicardipine plasma levels

ManagementMonitor BP carefully; consider an alternative H2-antagonist or PPI

FDA PI

Moderate Simvastatin / lovastatin

MechanismNicardipine inhibits CYP3A4-mediated statin metabolism

EffectIncreased statin exposure with greater risk of myopathy and rhabdomyolysis

ManagementLimit simvastatin dose if combined; consider switching to atorvastatin, rosuvastatin, or pravastatin

Lexicomp

Moderate PDE5 inhibitors (sildenafil, tadalafil)

MechanismAdditive vasodilation

EffectHypotension, particularly orthostatic

ManagementCounsel about timing of doses; ensure adequate hydration; consider PDE5 dose reduction

Lexicomp

Minor Grapefruit juice

MechanismInhibition of intestinal CYP3A4

EffectModest rise in nicardipine exposure

ManagementEffect is smaller than for felodipine, but advise patients to limit intake

Pharmacokinetic studies

Minor NSAIDs

MechanismSodium retention and reduced renal prostaglandin-mediated vasodilation

EffectModest attenuation of antihypertensive effect

ManagementLimit duration of NSAID; check BP if chronic NSAID is needed

Lexicomp

Mon

Monitoring

Blood Pressure IV: continual during titration, then frequently during steady infusion
Oral: weekly until stable, then routine BP visitsRoutine FDA label specifies BP and HR be monitored continually during IV infusion. For oral therapy, home BP averaging is preferred over single clinic readings to guide dose changes.
Heart Rate / Rhythm Continuous ECG during IV titration; baseline and at routine visits for oralRoutine Mean HR rises 7–8 bpm in placebo-controlled IV trials; reflex tachycardia is most common during rapid IV up-titration or oral initiation. Persistent HR > 110 bpm should prompt dose reduction or addition of a beta-blocker if appropriate.
IV Site Assessment Every 4–6 h during peripheral infusion; rotate site every 12 hRoutine Per FDA label, change peripheral infusion site every 12 h to minimize venous irritation, thrombosis, and phlebitis. Switch to central access for prolonged infusions.
Renal Function Baseline; recheck within 1–2 weeks of titrationRoutine Creatinine and eGFR; significant rises (> 30%) warrant dose review, particularly when nicardipine is co-administered with calcineurin inhibitors or in patients with renovascular disease.
Liver Function Tests Baseline; repeat if jaundice, dark urine, RUQ pain, or unexplained fatigueTrigger-based Drug-induced liver injury is rare; routine surveillance is unnecessary in healthy adults but advisable in pre-existing hepatic disease or with concurrent hepatotoxic agents. In cirrhosis, AUC is markedly higher and the elimination half-life is prolonged.
Peripheral Edema Each clinic visit; symptom-drivenRoutine Examine ankles and pretibial area; quantify (mild/moderate/severe). Distinguish vasodilator edema (bilateral, symmetric, evening-predominant) from cardiac, renal, or hepatic causes.
Symptoms of Angina At every visit, especially during initiation and titrationTrigger-based Per FDA label warning, ~7% of patients on oral IR develop increased angina on initiation or up-titration vs ~4% on placebo. Increasing frequency or intensity should prompt cardiac re-evaluation and a switch to an alternative agent.
Cyclosporine / Tacrolimus Levels Within 48–72 h of starting or stopping nicardipine; weekly until stableTrigger-based FDA label recommends close monitoring of plasma concentrations and dose reduction of cyclosporine or tacrolimus when nicardipine is co-administered. Tighter monitoring is warranted in renal transplant patients to avoid nephrotoxicity.
Fluid Balance (in pregnancy / preeclampsia) Every 4 h during IV nicardipine + magnesium useTrigger-based Pulmonary edema is a recognised concern when both agents are infused; restrict fluids to obstetric protocol limits and reassess respiratory status frequently.

Contraindications & Cautions

Absolute Contraindications

Known hypersensitivity to nicardipine or any component of the formulation
Advanced (severe) aortic stenosis — afterload reduction can reduce coronary perfusion pressure and worsen myocardial oxygen balance (per FDA label)

Relative Contraindications (Specialist Input Recommended)

Heart failure or significant LV dysfunction — per FDA label, nicardipine has shown a negative inotropic effect in some patients; use cautiously, particularly in combination with a beta-blocker
Acute myocardial infarction or unstable angina — short-acting dihydropyridine effects on coronary autoregulation may worsen ischaemia (oral IR carries a labelled warning of increased angina on initiation)
Severe hepatic impairment — per FDA label, nicardipine plasma levels and half-life are markedly increased in cirrhosis; SR has not been studied in severe liver disease
Concurrent strong CYP3A4 inhibitors — combination is not absolutely prohibited but requires dose reduction and tighter monitoring

Use with Caution

Mild-to-moderate hepatic impairment — start at the lower end of the dose range and lengthen the interval between titration steps
Renal impairment — IV clearance is lower and AUC higher in moderate impairment; titrate gradually
Older adults — increased orthostatic risk; avoid abrupt up-titration
Volume depletion or concurrent diuretic therapy — first-dose hypotension more likely
Acute cerebral infarction or hemorrhage — per FDA label, avoid systemic hypotension
Pregnancy — IV nicardipine has an established role in severe hypertension and preeclampsia in many protocols, but oral use for chronic hypertension is generally reserved for cases where labetalol or methyldopa are unsuitable
Lactation — small amounts transfer into breast milk; FDA labeling recommends against breastfeeding while taking nicardipine, although published case series suggest minimal infant exposure. Local prescribing guidance varies.
Beta-blocker withdrawal — nicardipine does not protect against rebound; beta-blockers should be tapered separately, preferably over 8–10 days

FDA Class-Wide Regulatory Warning Increased Angina with Short-Acting Dihydropyridines on Initiation

The FDA-approved labelling for oral nicardipine carries a Warning that approximately 7% of patients in short-term placebo-controlled angina trials experienced increased frequency, duration, or severity of angina on starting nicardipine or with up-titration, compared with about 4% on placebo. Comparisons with beta-blockers also showed a higher rate (4% vs 1%). This recognised class effect of short-acting dihydropyridines underpins the recommendation to avoid them in unstable angina, recent myocardial infarction, or severe obstructive coronary disease and to choose longer-acting agents where chronic vasodilation is required.

Patient Counselling

Purpose of Therapy

Patients should understand that nicardipine relaxes the small arteries throughout the body, lowering blood pressure and easing the workload of the heart. Whether prescribed for hypertension or angina, the goal is long-term reduction of cardiovascular events; patients are unlikely to “feel” the benefit, which is one reason adherence is so important. For those receiving the IV form in hospital, a brief explanation that it is a fast-acting version of a tablet they may eventually take at home helps demystify the infusion.

How to Take

Immediate-release capsules are taken three times daily, ideally at evenly spaced intervals; sustained-release capsules are taken twice daily and must be swallowed whole rather than crushed or chewed. The drug can be taken with or without food, although a high-fat meal can reduce absorption of the SR formulation. Doses should not be doubled if a dose is missed within a few hours of the next scheduled one. Abrupt discontinuation is discouraged because rebound hypertension or angina can occur — any planned cessation should be tapered with the prescriber’s input.

Headache

Tell patient Headache is one of the more common reasons for discontinuing the medicine, although in the most recent placebo-controlled SR trials the rate was similar to placebo. It usually starts within the first few days, tends to ease over 1–2 weeks, and responds to acetaminophen at standard doses.

Call prescriber If headache is severe, persistent beyond two weeks, or associated with vision changes, weakness, or vomiting.

Ankle and Leg Swelling

Tell patient Swelling around the ankles can occur because the small blood vessels relax and let fluid move into the tissues. It is usually worse later in the day and improves with leg elevation; it is not a sign of heart failure or kidney problems.

Call prescriber If swelling is asymmetric, painful, accompanied by shortness of breath, or rapidly worsening — these may suggest a different cause.

Dizziness or Lightheadedness

Tell patient This is most likely after the first dose, after a dose increase, or when standing up quickly from sitting or lying down. Rise slowly, sit at the edge of the bed for a minute before standing, and avoid activities that need full alertness until the response is established.

Call prescriber If dizziness is associated with fainting, chest pain, palpitations, or a fall.

Flushing and Sensation of Warmth

Tell patient Brief flushing of the face and upper chest often happens within an hour of a dose. It is harmless and tends to settle within a couple of weeks of regular therapy.

Call prescriber If flushing is accompanied by hives, swelling of the lips or tongue, or trouble breathing — possible allergic reaction.

Palpitations

Tell patient A faster heartbeat can occur because the medication relaxes blood vessels; the body briefly compensates by speeding up the heart. This usually settles within a few days, especially with the sustained-release form.

Call prescriber If the heart races persistently, you feel your heart skipping beats, or you develop chest pain or shortness of breath.

Worsening Chest Pain

Tell patient For patients taking nicardipine for angina, the medication should reduce — not increase — chest pain over time. About 7% of people may experience increased angina on first starting the drug or after a dose increase.

Call prescriber Urgently, if chest pain becomes more frequent, more severe, occurs at rest, or fails to respond to nitroglycerin within 5 minutes — call emergency services.

Grapefruit and Other Drugs

Tell patient Limit grapefruit and grapefruit juice while on this medication, as they can raise drug levels and increase side effects. Always tell the pharmacist about new prescriptions, over-the-counter medicines, or supplements (especially St John’s wort).

Call prescriber Before starting any new medicine, including herbal supplements, antibiotics, or antifungal pills.

Stopping the Medication

Tell patient Do not stop suddenly. If you wish to discontinue — whether because of side effects, surgery, or switching medications — speak to the prescriber first so the dose can be tapered safely.

Call prescriber Before any planned dose change; immediately if you have run out of medicine.

Lifestyle Reminders

Tell patient Continue lifestyle measures — moderate sodium intake, regular aerobic activity, weight management, limiting alcohol, and not smoking — which amplify the benefit of any antihypertensive. Home BP monitoring two or three times a week, with readings averaged, is useful for the next clinic visit.

Call prescriber If home BP readings are consistently outside the agreed target range (high or low) over more than a week.

Ref

Sources

Regulatory (PI / SmPC)

U.S. Food and Drug Administration. Cardene SR (nicardipine hydrochloride) sustained-release capsules — Full Prescribing Information. accessdata.fda.gov Authoritative source for FDA-approved oral SR indications, dosing, pharmacokinetics, and the placebo-controlled adverse-reaction tables cited in this monograph.
U.S. Food and Drug Administration. Cardene I.V. (nicardipine hydrochloride) Premixed Injection — Full Prescribing Information. accessdata.fda.gov Authoritative reference for IV titration schedules, oral-to-IV dose equivalence, infusion-related adverse events, and the IV adverse-reaction table (n=144 vs n=100).
U.S. Food and Drug Administration. Cardene IV (nicardipine hydrochloride in dextrose / sodium chloride injection) — current label via DailyMed. dailymed.nlm.nih.gov Up-to-date labelling for premixed IV formulations including indications, dosing, drug interactions and adverse reactions.
U.S. Food and Drug Administration. Nicardipine hydrochloride capsules (immediate-release, generic) — current PI via DailyMed/drugs.com. drugs.com (FDA-sourced PI) FDA-sourced prescribing information for IR oral nicardipine, used here for IR-specific dosing, indications (chronic stable angina), and the increased-angina warning.

Key Clinical Trials

Peacock WF, Hilleman DE, Levy PD, Rhoney DH, Varon J. A systematic review of nicardipine vs labetalol for the management of hypertensive crises. American Journal of Emergency Medicine. 2012;30(6):981-993. doi.org/10.1016/j.ajem.2011.06.040 Systematic review supporting comparable BP control and a more predictable response with nicardipine versus labetalol in hypertensive crises.
Peacock WF, Varon J, Baumann BM, et al. CLUE: a randomized comparative effectiveness trial of IV nicardipine versus labetalol use in the emergency department. Critical Care. 2011;15(3):R157. doi.org/10.1186/cc10289 Multicentre randomised trial demonstrating that more nicardipine patients reach the physician-specified target BP within 30 minutes than those receiving labetalol.
Neutel JM, Smith DH, Wallin D, et al. A comparison of intravenous nicardipine and sodium nitroprusside in the immediate treatment of severe hypertension. American Journal of Hypertension. 1994;7(7 Pt 1):623-628. doi.org/10.1093/ajh/7.7.623 Randomised comparison showing comparable BP-lowering with fewer dose adjustments and fewer side effects for IV nicardipine versus nitroprusside.
Elatrous S, Nouira S, Ouanes Besbes L, et al. Short-term treatment of severe hypertension of pregnancy: prospective comparison of nicardipine and labetalol. Intensive Care Medicine. 2002;28(9):1281-1286. doi.org/10.1007/s00134-002-1406-3 Randomised prospective trial in 60 women showing nicardipine and labetalol are both effective and safe for the initial management of severe hypertension in pregnancy.
Cannon CM, Levy P, Baumann BM, et al. Intravenous nicardipine and labetalol use in hypertensive patients with signs or symptoms suggestive of end-organ damage in the emergency department: a subgroup analysis of the CLUE trial. BMJ Open. 2013;3(3):e002338. PMID: 23535700 Subgroup analysis showing nicardipine more often achieved target SBP within 30 minutes in patients with suspected end-organ damage.

Guidelines

Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults. Hypertension. 2018;71(6):e13-e115. doi.org/10.1161/HYP.0000000000000065 Defines hypertension thresholds and treatment targets that frame all chronic and acute use of nicardipine in adult cardiology.
Mancia G, Kreutz R, Brunström M, et al. 2023 ESH Guidelines for the management of arterial hypertension. Journal of Hypertension. 2023;41(12):1874-2071. doi.org/10.1097/HJH.0000000000003480 European hypertension guideline informing the place of dihydropyridine CCBs in chronic and emergency settings.
Hoh BL, Ko NU, Amin-Hanjani S, et al. 2023 Guideline for the Management of Patients with Aneurysmal Subarachnoid Hemorrhage: A Guideline from the American Heart Association/American Stroke Association. Stroke. 2023;54(7):e314-e370. doi.org/10.1161/STR.0000000000000436 Multidisciplinary guideline relevant to the off-label use of intra-arterial and IV nicardipine for cerebral vasospasm and BP control after aSAH.
American College of Obstetricians and Gynecologists. ACOG Practice Bulletin No. 222: Gestational Hypertension and Preeclampsia. Obstetrics & Gynecology. 2020;135(6):e237-e260. doi.org/10.1097/AOG.0000000000003891 US obstetric guideline supporting IV nicardipine as a recognised option for severe acute-onset hypertension in pregnancy.

Mechanistic / Basic Science

Sorkin EM, Clissold SP. Nicardipine: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the treatment of angina pectoris, hypertension and related cardiovascular disorders. Drugs. 1987;33(4):296-345. doi.org/10.2165/00003495-198733040-00002 Foundational pharmacology review still cited for the vascular-selectivity profile and comparative dihydropyridine effects of nicardipine.
Triggle DJ. Calcium channel antagonists: clinical uses—past, present and future. Biochemical Pharmacology. 2007;74(1):1-9. doi.org/10.1016/j.bcp.2007.01.016 Review of the L-type calcium channel pharmacology that underpins the vascular selectivity of dihydropyridines including nicardipine.

Pharmacokinetics / Special Populations

Graham DJ, Dow RJ, Freedman D, et al. Pharmacokinetics of nicardipine following oral and intravenous administration in man. Postgraduate Medical Journal. 1984;60(Suppl 4):7-10. Original pharmacokinetic study describing the multi-exponential IV decline and high oral first-pass metabolism quoted in this monograph.
Flynn JT, Tullus K. Severe hypertension in children and adolescents: pathophysiology and treatment. Pediatric Nephrology. 2009;24(6):1101-1112. doi.org/10.1007/s00467-008-1000-1 Reference for off-label paediatric IV nicardipine dosing in hypertensive crisis in critical-care settings.
Flynn JT, Mottes TA, Brophy PD, Kershaw DB, Smoyer WE, Bunchman TE. Intravenous nicardipine for treatment of severe hypertension in children. Journal of Pediatrics. 2001;139(1):38-43. doi.org/10.1067/mpd.2001.114030 Retrospective review of 29 children that informs the paediatric dose ranges (mean effective ~1.8 mcg/kg/min) cited in this monograph.
Lexicomp Online. Nicardipine: drug information. Wolters Kluwer Clinical Drug Information, Hudson, OH. (Subscription resource.) Cross-reference for clinically actionable drug-interaction severities and management recommendations beyond the FDA label.